Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings

Siegel, 2018, Cancer statistics, 2018, CA Cancer J. Clin., 67, 7, 10.3322/caac.21387 Baselga, 2014, Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer, J. Clin. Oncol., 32, 3753, 10.1200/JCO.2013.54.5384 Saad, 2010, Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials, J. Clin. Oncol., 28, 1958, 10.1200/JCO.2009.25.5414 Thientosapol, 2013, Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials, Internal Med. J., 43, 883, 10.1111/imj.12178 National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assesment: Breast and ovarian. 2017;Version 2.2017. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed July 25, 2017. Atchley, 2008, Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, J. Clin. Oncol., 26, 4282, 10.1200/JCO.2008.16.6231 Musolino, 2007, BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study, Breast, 16, 280, 10.1016/j.breast.2006.12.003 Pellegrino, 2016, Triple negative status and BRCA mutations in contralateral breast cancer: A population-based study, Acta Biomed., 87, 54 Peshkin, 2010, BRCA1/2 mutations and triple negative breast cancers, Breast Dis., 32, 25 Evans, 2011, Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer, J. Med. Genet., 48, 520, 10.1136/jmedgenet-2011-100006 Saura, 2010, High prevalence of BRCA1/2 germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history, ASCO Meeting Abstracts, 28, 1534 Couch, 2015, Inherited mutations in 17 breast cancer susceptibility Genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, J. Clin. Oncol., 33, 304, 10.1200/JCO.2014.57.1414 Brekelmans, 2007, Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases, Eur. J. Cancer, 43, 867, 10.1016/j.ejca.2006.12.009 Iglehart, 2009, Synthetic lethality—A new direction in cancer-drug development, N. Engl. J. Med.., 361, 189, 10.1056/NEJMe0903044 Robson, 2017, Olaparib for metastatic breast cancer in patients with a germline BRCA mutation, N. Engl. J. Med., 377, 523, 10.1056/NEJMoa1706450 Scott, 2015, Poly (ADP-ribose) polymerase inhibitors: Recent advances and future development, J. Clin. Oncol., 33, 1397, 10.1200/JCO.2014.58.8848 Litton, 2018, Talazoparib in patients with advanced breast cancer and a germline BRCA mutation, N. Engl. J. Med., 379, 753, 10.1056/NEJMoa1802905 Ettl, 2018, Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial, Ann. Oncol., 29, 1939, 10.1093/annonc/mdy257 Kaklamani, 2017, Treatment patterns and associated adverse events among patients with metastatic triple-negative breast cancer, J. Clin. Oncol., 35, e12576, 10.1200/JCO.2017.35.15_suppl.e12576 Sablin, 2017, Triple-NOTE (Triple negative outcome in ESME): Large recent real-world prognostic data on triple negative metastatic breast cancers (mTNBC), J. Clin. Oncol., 35, e12592, 10.1200/JCO.2017.35.15_suppl.e12592 O'Shaughnessy, 2014, Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer, J. Clin. Oncol., 32, 3840, 10.1200/JCO.2014.55.2984 Di Leo, 2014, Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial, J. Natl. Cancer Inst., 106, djt337, 10.1093/jnci/djt337 Mehta, 2012, Combination anastrozole and fulvestrant in metastatic breast cancer, N. Engl. J. Med., 367, 435, 10.1056/NEJMoa1201622